Percutaneous radiofrequency ablation for treatment of hepatocellular carcinoma
Xie X, Dendukuri N, McGregor M
Record ID 32010000172
English
Authors' recommendations:
For relatively early liver cancer where either SRS or PRFA are available options, the evidence suggests that survival rates are comparable. However, several cohort studies (with possible selection bias) suggest that recurrence rates are higher and disease free survival shorter following PRFA than SRS. Complications are significantly more frequentand hospitalization significantly longer following SRS. The costs of PRFA are $7,244 less per case than SRS (to the MUHC). Note that any potential budgetary saving resultingfrom use of PRFA would not be realized but would result in an increase in other types of surgical procedures, thus causing an increase in efficiency.
Details
Project Status:
Completed
URL for project:
http://www.mcgill.ca/files/tau/RFA_and_Liver_Cancer_FINAL.pdf
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Carcinoma, Hepatocellular
- Catheter Ablation
- Liver Neoplasms
Contact
Organisation Name:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
Contact Address:
Technology Assessment Unit of the MUHC, Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve, Bureau 3F.50, Montreal, Quebec H4A 3S5
Contact Name:
nandini.dendukuri@mcgill.ca
Contact Email:
nandini.dendukuri@mcgill.ca
Copyright:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.